Best Short-Acting Beta Agonist (SABA) for Asthma

Primary Recommendation: Albuterol

The American College of Allergy, Asthma, and Immunology recommends albuterol as the preferred SABA for asthma management across all age groups and severity levels, with the most extensive safety data and clinical experience, particularly during pregnancy where it has the greatest reassuring evidence 1
The National Asthma Education and Prevention Program (NAEPP) guidelines specifically identify albuterol as the preferred short-acting inhaled beta-2-agonist because it has "the greatest amount of data related to safety during pregnancy of any currently available" SABA, though this recommendation extends to general asthma management 1
Both the 2020 NAEPP guidelines and current management algorithms consistently recommend "PRN SABA" (as-needed short-acting beta-agonist) across all treatment steps, with albuterol being the standard agent referenced 2, 3

Increasing SABA use or use >2 days per week for symptom relief (not prevention of exercise-induced bronchoconstriction) indicates inadequate asthma control and necessitates stepping up anti-inflammatory therapy, according to the NAEPP 2, 3
Standard albuterol dosing is 2 actuations (180 μg total) as needed for symptoms, up to 3 treatments at 20-minute intervals for acute symptoms, as recommended by the NAEPP 2, 3
Maximum recommended daily dose should not exceed 8 puffs (36 mcg) when used as maintenance plus rescue, as recommended by the NAEPP 2, 3

For patients ≥12 years with mild persistent asthma (Step 2), as-needed ICS-formoterol used concomitantly is a conditionally recommended alternative to daily low-dose ICS plus SABA reliever, according to the Global Initiative for Asthma (GINA) 4
At Steps 3-4, ICS-formoterol can serve as both maintenance and reliever therapy (SMART approach), with formoterol's rapid onset making it suitable for acute symptom relief, as recommended by the NAEPP and GINA 2, 3, 5